Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
FRTX was delisted on the 18th of December, 2023.
25 hedge funds and large institutions have $4.4M invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 3 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
54% more capital invested
Capital invested by funds: $2.86M → $4.4M (+$1.54M)
47% more funds holding
Funds holding: 17 → 25 (+8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$931K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$458K |
| 3 |
Millennium Management
New York
|
+$228K |
| 4 |
Renaissance Technologies
New York
|
+$181K |
| 5 |
TI
Telemetry Investments
New York
|
+$137K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$652K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$21.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$12K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$2K |
FRTX Hedge Fund Activity: Q4 2020 in Review
25 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q4 2020, worth a combined $4.4M — up 54% from $2.86M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new FRTX positions and 3 closed out — a net gain of 8 holders — while 6 added to existing stakes and 1 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $931K. The largest seller was Sabby Management, exiting entirely with an estimated $652K sold.
- 25 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q4 2020, up from 17 in Q3 2020.
- Funds reported $4.4M of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q4 2020, up 54% quarter-over-quarter.
- 11 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q4 2020 and 3 closed out, a net change of +8 holders.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q4 2020 was Anson Funds Management, an estimated $931K added.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q4 2020 was Sabby Management, an estimated $652K sold.
Based on aggregated 13F filings for Q4 2020.